MedTrace Logo

Real-world Evaluation of the Effectiveness of Immunoglobulin-Histamine Complex, IHC (Histoglob) in Chronic Urticaria

NCT07680413 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2026-07-02

No results posted yet for this study

Summary

This is a prospective, multicentre, non-interventional, observational, real-world evidence (RWE) study designed to evaluate the effectiveness and safety of Immunoglobulin/Histamine Complex (IHC) in patients with Chronic Urticaria in India.

Conditions

  • Chronic Urticaria

Interventions

DRUG

Antihistaminics, H2 blockers, Leukotriene antagonists, Immunoglobulin/Histamine Complex (IHC) Injection

Histaglobulin prefilled syringe is administered subcutaneously as a single 1mL dose.

Sponsors & Collaborators

  • Innvocept Global Solutions Private Limited

    collaborator OTHER

  • Bharat Serums and Vaccines Limited

    lead INDUSTRY

Principal Investigators

  • Dr Saswata Banerjee · Bharat serums and Vaccines LTd

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2026-09-30
Completion
2026-11-30

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07680413 on ClinicalTrials.gov